IPHA
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Graham Number is N/A due to negative earnings and book value.
- P/B of -5.18
- P/S of 14.69 is expensive for declining revenue
Growth metrics are sharply negative, contradicting analyst optimism.
- High analyst price target ($6.00)
- Revenue growth -46.7% YoY
Consistent long-term value destruction and failure to meet estimates.
- 5Y Change -67.1%
- Average earnings surprise -229.65%
F-Score of 3 indicates weak financial health and operational instability.
- Current ratio > 1
- Piotroski F-Score 3/9
- ROA -38.85%
Non-dividend paying biotech.
- No dividend payments
- 0/100 strength score
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IPHA and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IPHA
Innate Pharma S.A.
Primary
|
-67.1% | -58.3% | -22.5% | -30.5% | -9.0% | +2.9% |
|
EMPG
Empro Group Inc.
Peer
|
+299.1% | +299.1% | +299.1% | -2.2% | 0.0% | 0.0% |
|
AGEN
Agenus Inc.
Peer
|
-93.5% | -88.0% | +124.2% | -10.7% | +36.6% | +18.4% |
|
HYPR
Hyperfine, Inc.
Peer
|
-88.1% | -17.1% | +81.4% | -30.9% | +2.5% | +7.1% |
|
FONR
FONAR Corporation
Peer
|
+3.3% | +15.4% | +48.2% | +20.1% | +0.7% | +0.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IPHA
Innate Pharma S.A.
|
BEARISH | $132.24M | - | -% | -% | $1.41 | |
|
EMPG
Empro Group Inc.
|
NEUTRAL | $143.05M | 192.89 | 66.3% | 13.7% | $17.36 | Compare |
|
AGEN
Agenus Inc.
|
BEARISH | $144.21M | - | -% | -32.9% | $3.99 | Compare |
|
HYPR
Hyperfine, Inc.
|
NEUTRAL | $119.21M | - | -79.0% | -262.3% | $1.21 | Compare |
|
FONR
FONAR Corporation
|
NEUTRAL | $117.26M | 16.18 | 6.0% | 7.1% | $18.61 | Compare |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning IPHA from our newsroom.